JP6784669B2 - 炎症性腸疾患及びセリアック病から過敏性腸症候群を識別するための方法及びシステム - Google Patents

炎症性腸疾患及びセリアック病から過敏性腸症候群を識別するための方法及びシステム Download PDF

Info

Publication number
JP6784669B2
JP6784669B2 JP2017518834A JP2017518834A JP6784669B2 JP 6784669 B2 JP6784669 B2 JP 6784669B2 JP 2017518834 A JP2017518834 A JP 2017518834A JP 2017518834 A JP2017518834 A JP 2017518834A JP 6784669 B2 JP6784669 B2 JP 6784669B2
Authority
JP
Japan
Prior art keywords
antibody
ibs
vincurin
cdtb
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017518834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531801A (ja
JP2017531801A5 (enExample
Inventor
マーク ピメンテル
マーク ピメンテル
クリストファー チャン
クリストファー チャン
Original Assignee
シーダーズ−サイナイ メディカル センター
シーダーズ−サイナイ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーダーズ−サイナイ メディカル センター, シーダーズ−サイナイ メディカル センター filed Critical シーダーズ−サイナイ メディカル センター
Publication of JP2017531801A publication Critical patent/JP2017531801A/ja
Publication of JP2017531801A5 publication Critical patent/JP2017531801A5/ja
Application granted granted Critical
Publication of JP6784669B2 publication Critical patent/JP6784669B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017518834A 2014-10-09 2015-10-08 炎症性腸疾患及びセリアック病から過敏性腸症候群を識別するための方法及びシステム Active JP6784669B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462061877P 2014-10-09 2014-10-09
US62/061,877 2014-10-09
US201462085825P 2014-12-01 2014-12-01
US62/085,825 2014-12-01
PCT/US2015/054655 WO2016057772A1 (en) 2014-10-09 2015-10-08 Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Publications (3)

Publication Number Publication Date
JP2017531801A JP2017531801A (ja) 2017-10-26
JP2017531801A5 JP2017531801A5 (enExample) 2017-12-07
JP6784669B2 true JP6784669B2 (ja) 2020-11-11

Family

ID=55653760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518834A Active JP6784669B2 (ja) 2014-10-09 2015-10-08 炎症性腸疾患及びセリアック病から過敏性腸症候群を識別するための方法及びシステム

Country Status (16)

Country Link
US (2) US10132814B2 (enExample)
EP (1) EP3204771B1 (enExample)
JP (1) JP6784669B2 (enExample)
KR (1) KR102426541B1 (enExample)
CN (1) CN107003308B (enExample)
AU (1) AU2015330872B2 (enExample)
CA (1) CA2962493C (enExample)
ES (1) ES3028294T3 (enExample)
IL (1) IL251606B (enExample)
MX (1) MX384921B (enExample)
NZ (1) NZ730490A (enExample)
PL (1) PL3204771T3 (enExample)
PT (1) PT3204771T (enExample)
RU (1) RU2706361C2 (enExample)
SG (1) SG11201702395WA (enExample)
WO (1) WO2016057772A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
MX383428B (es) 2012-09-17 2025-03-13 Cedars Sinai Medical Center Determinaciòn de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia.
KR102259588B1 (ko) 2013-10-09 2021-06-02 세다르스-신나이 메디칼 센터 과민성 장 증후군 및 염증성 장 질환의 진단 및 치료
MX384921B (es) 2014-10-09 2025-03-14 Cedars Sinai Medical Center Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
EP3913371A1 (en) 2020-05-18 2021-11-24 Neuroimmun GmbH Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions
CN113447649B (zh) * 2021-07-01 2022-04-19 浙江大学 一种检测抗粘着斑蛋白-IgG抗体的试剂盒

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5691151A (en) 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
US20040018528A1 (en) 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
EP1617846A1 (en) * 2003-04-08 2006-01-25 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
EP2280285A1 (en) 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
ES2456710T3 (es) 2003-12-05 2014-04-23 Fuso Pharmaceutical Industries Ltd. Genes de toxinas de distensión citoletales como dianas para la detección de bacterias Campylobacter
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP2102367A2 (en) 2006-11-09 2009-09-23 XDX, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
JP2011507509A (ja) * 2007-12-20 2011-03-10 インデックス・ダイアグノスティックス・エイビイ Ｉｂｄとｉｂｓとの区別、ｉｂｄの疾患タイプ間の更なる識別における使用する方法およびキット
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
WO2010060098A1 (en) 2008-11-24 2010-05-27 Cedars-Sinai Medical Center Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof
BRPI1008058A8 (pt) 2009-02-11 2018-03-27 Cedars Sinai Medical Center uso de antibióticos para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
JP5477671B2 (ja) 2012-02-28 2014-04-23 三菱マテリアル株式会社 サーミスタ用金属窒化物材料及びその製造方法並びにフィルム型サーミスタセンサ
MX383428B (es) * 2012-09-17 2025-03-13 Cedars Sinai Medical Center Determinaciòn de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia.
KR102259588B1 (ko) 2013-10-09 2021-06-02 세다르스-신나이 메디칼 센터 과민성 장 증후군 및 염증성 장 질환의 진단 및 치료
MX384921B (es) 2014-10-09 2025-03-14 Cedars Sinai Medical Center Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
EP3573650A4 (en) 2017-01-30 2020-12-09 Cedars-Sinai Medical Center DIAGNOSIS OF SCLERODERMIA

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Also Published As

Publication number Publication date
JP2017531801A (ja) 2017-10-26
KR102426541B1 (ko) 2022-07-29
CA2962493A1 (en) 2016-04-14
AU2015330872A1 (en) 2017-04-13
IL251606B (en) 2020-08-31
WO2016057772A1 (en) 2016-04-14
US20190187153A1 (en) 2019-06-20
NZ730490A (en) 2021-07-30
EP3204771A4 (en) 2018-03-14
CN107003308B (zh) 2020-02-11
KR20170067795A (ko) 2017-06-16
CN107003308A (zh) 2017-08-01
AU2015330872B2 (en) 2021-04-22
MX2017004516A (es) 2017-10-12
RU2706361C2 (ru) 2019-11-18
EP3204771B1 (en) 2025-03-12
SG11201702395WA (en) 2017-04-27
ES3028294T3 (en) 2025-06-18
MX384921B (es) 2025-03-14
CA2962493C (en) 2023-01-10
US10690679B2 (en) 2020-06-23
PT3204771T (pt) 2025-05-20
US20160103136A1 (en) 2016-04-14
EP3204771A1 (en) 2017-08-16
PL3204771T3 (pl) 2025-07-28
RU2017115663A3 (enExample) 2019-05-16
RU2017115663A (ru) 2018-11-13
IL251606A0 (en) 2017-06-29
US10132814B2 (en) 2018-11-20

Similar Documents

Publication Publication Date Title
JP6784669B2 (ja) 炎症性腸疾患及びセリアック病から過敏性腸症候群を識別するための方法及びシステム
KR102259588B1 (ko) 과민성 장 증후군 및 염증성 장 질환의 진단 및 치료
Garcia et al. Sensitivity and specificity of a blood and urine galactomannan antigen assay for diagnosis of systemic aspergillosis in dogs
EP2904395B1 (en) Antibodies to microbiome as diagnostic markers for ibs
KR102203568B1 (ko) 장 및 방광의 운동 장애 및 섬유근육통의 진단 및 치료
KR20190111094A (ko) 경피증의 진단
US20240159772A1 (en) Methods for Detecting and Treating Irritable Bowel Syndrome
Matsui et al. Development of serological assays to identify Helicobacter suis and H. pylori infections
US20210349094A1 (en) Detection of autoreactive fecal immunoglobulin a (iga) for diagnosis of lupus
CN111032053A (zh) 靶向defa5抗体和用于诊断和治疗炎性肠病的测定方法
JP6193976B2 (ja) バイオマーカーとしてのクロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）・デヒドロゲナーゼおよび毒素
HK1234824B (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
HK1234824A1 (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
HK1213050B (en) Antibodies to microbiome as diagnostic markers for ibs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180911

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200619

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201023

R150 Certificate of patent or registration of utility model

Ref document number: 6784669

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250